How a Rare Pediatric Trial Achieved Rapid Recruitment: A Real-World Case Study

Background: The Challenge of Recruiting in Rare Pediatric Disorders

Recruiting pediatric patients for rare disease trials is among the most complex tasks in clinical research. The small population size, strict eligibility criteria, and logistical and ethical considerations make it difficult to meet enrollment targets. When the condition is ultra-rare and affects children, the challenges multiply—requiring innovative, patient-centric approaches that prioritize caregivers, regulatory compliance, and feasibility.

This case study explores the recruitment strategies and outcomes of a recent Phase II trial for Congenital Hyperinsulinism (CHI), a rare genetic disorder affecting approximately 1 in 50,000 children globally. The disorder leads to dangerously low blood sugar levels in infants and young children and requires urgent intervention to prevent neurological damage.

Trial Design and Recruitment Objectives

The sponsor—a mid-sized biotech company—initiated a multi-country Phase II clinical trial of an oral investigational agent targeting KATP-channel mutations common in CHI. The trial targeted 20 pediatric patients, aged 6 months to 10 years, across five countries (USA, UK, India, Poland, and Brazil).

Primary recruitment goals:

• Enroll 20 qualified pediatric participants in 6 months
• Ensure diversity across genetic backgrounds and geographies
• Minimize site burden and caregiver dropout
• Achieve protocol compliance with limited in-clinic visits

Challenges identified included limited public awareness, diagnostic delays, logistical constraints for travel, and ethical concerns around informed consent and pediatric assent.

Pre-Recruitment Preparation and Site Selection

The sponsor adopted a proactive recruitment strategy, beginning with extensive feasibility assessments and pre-screening through pediatric endocrinology clinics and genetic counseling centers. Criteria for site selection included:

• Prior experience with pediatric rare disease trials
• Availability of genetic testing for ABCC8 and KCNJ11 mutations
• Established relationships with patient advocacy groups
• Infrastructure to support remote visit models

Five trial sites were selected across four continents, each trained in protocol delivery, eConsent tools, and pediatric engagement techniques. Site-specific modifications were approved by local IRBs to address regional nuances in caregiver involvement and data privacy regulations.

Engaging Advocacy Groups and Registries

Collaboration with advocacy groups played a vital role in generating trial awareness. The sponsor partnered with Congenital Hyperinsulinism International (CHI International) and Rare Kids Global to:

• Distribute IRB-approved recruitment materials in newsletters and websites
• Host webinars with principal investigators for caregivers
• Send pre-screening questionnaires to registry members with opt-in consent

These efforts resulted in over 180 interested caregivers responding within the first 30 days of the campaign. 44 met initial eligibility based on age, diagnosis, and treatment history.

Implementing Remote and Hybrid Trial Models

To reduce site visits and improve participation among families with young children, the sponsor implemented a hybrid model with decentralized components:

• Home nurse visits for blood glucose monitoring and sample collection
• Telemedicine appointments for physician assessments and dosing instructions
• Direct-to-patient investigational product shipments with nurse support

Outcomes from this model included:

• 85% of study visits conducted remotely
• Only two site visits required: screening and final assessment
• Zero missed visits or dose interruptions

Such flexibility was especially impactful for participants in remote areas of Brazil and rural India, where travel was previously a barrier to participation.

Ethical and Regulatory Considerations in Pediatric Enrollment

Given the age group, additional safeguards were built into the informed consent and assent processes. These included:

• Caregiver-facing video modules explaining trial expectations
• Child assent forms with visuals and simplified language for children aged 7+
• Local translations of all study materials, reviewed by cultural liaisons

Example Consent Tool Snapshot:

These tailored approaches helped ensure full comprehension and voluntary participation, satisfying IRB and GCP expectations.

Recruitment Outcomes and Key Metrics

The recruitment phase was completed in just 4.5 months—6 weeks ahead of schedule. Key results:

• 20 participants enrolled from 5 countries
• Zero withdrawals during the treatment phase
• Average caregiver satisfaction rating: 9.4/10
• No major protocol deviations or ethics queries raised

Feedback from sites indicated that the hybrid model and advocacy support were central to this success. Caregivers appreciated the ability to stay home, while maintaining access to a well-coordinated care team and trial support services.

Lessons Learned and Future Applications

This trial underscores the importance of planning, flexibility, and caregiver engagement in rare pediatric recruitment. Key takeaways for future studies:

• Start community engagement early—months before site initiation
• Partner with both global and local advocacy organizations
• Design study protocols with remote data collection options from the outset
• Respect cultural and linguistic diversity in materials and communication
• Empower caregivers with support tools, FAQs, and transparency

The sponsor has since expanded this recruitment model to other pediatric rare diseases, including Leigh Syndrome and Smith-Lemli-Opitz Syndrome, with similarly promising outcomes.

Conclusion: Proving That Pediatric Rare Trial Recruitment Can Succeed

Recruitment in pediatric rare disease trials may seem daunting, but with the right strategies—centered on flexibility, advocacy, ethics, and digital tools—success is not only possible but scalable. This case study demonstrates that when sponsors meet families where they are, and build trials around their needs, recruitment becomes not just faster, but more humane, inclusive, and effective.

Effective Recruitment Strategies in Pediatric Clinical Trials

Recruiting children for clinical trials is uniquely complex due to ethical, legal, and psychological considerations. Pediatric trials often require parental or guardian consent, child assent, and additional regulatory oversight, all while addressing the concerns of families. Successful recruitment in pediatric studies demands innovative, compassionate, and highly regulated approaches. In this guide, we explore comprehensive recruitment strategies that balance ethics, engagement, compliance, and operational excellence in pediatric clinical trials.

Why Pediatric Trials Require Special Recruitment Approaches

Pediatric trials differ significantly from adult studies. The recruitment process must navigate several layers:

• Parental or guardian informed consent and child assent
• Heightened IRB scrutiny for ethical compliance
• Special considerations for child welfare and safety
• Family logistical challenges (school, travel, financial burden)
• Limited eligible population and rare disease incidence in children

These factors necessitate thoughtful and family-centered recruitment strategies.

1. Develop Age-Appropriate and Family-Centered Materials

Recruitment materials should be tailored for both caregivers and child participants. Best practices include:

• Creating colorful, illustrated brochures or videos for children
• Using plain-language explanations suitable for different age groups
• Preparing detailed FAQ documents for parents
• Including testimonials from other parents or pediatric patients

Materials must be reviewed and approved by an IRB and written in accordance with pharma regulatory compliance standards.

2. Engage Pediatricians and Primary Care Providers

Family trust in healthcare professionals plays a pivotal role in pediatric recruitment. Strategies to involve pediatricians include:

• Providing training on protocol and eligibility criteria
• Offering toolkits with referral materials
• Sharing safety data from earlier phases
• Providing incentives for referring patients (as allowed by law)

Clinician advocates are often the most effective bridge to families unfamiliar with research participation.

3. Emphasize Ethical and Legal Considerations

Ethical recruitment in pediatric trials requires compliance with laws governing minors. This includes:

• Obtaining written parental consent and verbal/written assent from the child
• Providing clear explanations of risks, benefits, and voluntariness
• Ensuring minimal risk procedures wherever possible
• Compensating time and effort without undue influence

As per CDSCO and USFDA guidelines, documentation of consent and assent must be retained and auditable throughout the trial lifecycle.

4. Address Family Logistical and Emotional Barriers

Recruitment fails when families are unable to overcome the practical burdens of participation. Sponsors and CROs should:

• Offer transportation or home visit services
• Provide child care support for siblings during visits
• Schedule visits after school or on weekends
• Design child-friendly environments at study sites
• Provide age-appropriate incentives like toys, certificates, or recognition programs

5. Use Digital Outreach and Community Engagement

Digital platforms are effective for raising awareness and engaging with families. Strategies include:

• Targeted Facebook and Instagram ads for parents
• Collaborations with parenting forums, blogs, and influencers
• Search engine ads using disease-specific keywords
• Geo-targeted messaging to reach families near sites

Ensure digital tools used in outreach campaigns are validated under CSV validation protocol and that data privacy laws (COPPA, HIPAA, GDPR) are fully complied with.

6. Collaborate with Schools and Pediatric Advocacy Organizations

Outreach through trusted institutions can boost credibility and access:

• Host information sessions at schools with parental consent
• Distribute IRB-approved flyers in pediatric clinics or community centers
• Partner with organizations like the American Academy of Pediatrics (AAP) or Rare Disease Pediatric Groups
• Use existing patient registries maintained by advocacy networks

7. Ensure Trial Design Minimizes Pediatric Burden

Trial protocols should be specifically designed for pediatric feasibility. Considerations include:

• Shorter visit durations and reduced blood draw volumes
• Use of topical anesthetics for procedures like injections
• Decentralized trial options like remote monitoring
• Gamified electronic diaries or tablets for patient-reported outcomes

Trials that include Stability Studies in pediatric populations should clearly explain sample handling, long-term storage, and how personal data is anonymized.

8. Train Staff in Pediatric Sensitivity and Communication

Staff must be trained not only on protocol but on interacting with minors and their families:

• Use positive reinforcement and clear communication styles
• Maintain a warm, non-threatening demeanor
• Understand developmental stages and comfort levels of different age groups
• Conduct trial simulations with pediatric participants for feedback

9. Monitor and Adapt Recruitment in Real-Time

Recruitment should be tracked continuously to identify drop-offs or barriers. Techniques include:

• Recruitment dashboards with geo-location data
• Real-time monitoring of digital ad performance
• Feedback loops from families and staff at each visit
• Adaptive campaign strategies based on enrollment velocity

10. Document and Share Recruitment Learnings

Each pediatric trial offers valuable lessons. Sponsors and CROs should:

• Document what strategies worked and why
• Share findings in industry roundtables or publications
• Refine future protocols based on recruitment insights
• Include pediatric recruitment best practices in Pharma SOP templates

Conclusion: Compassion Meets Compliance

Pediatric clinical trials are a vital component of medical advancement but demand careful planning and ethical sensitivity. Recruitment strategies must center the child and their family at every step—from first contact to trial closure. By applying patient-centric design, regulatory rigor, and continuous engagement, clinical teams can accelerate enrollment while safeguarding the dignity and rights of their youngest participants.